GLPwatch

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice

NCT04862923 · Completed

Last updated 2026-05-28

This study is testing how an oral medication called semaglutide affects blood sugar levels in adults with type 2 diabetes in the United Kingdom as part of routine medical care.

Status Completed The study has finished.
Type Observational
Participants 336 people
Who can join Ages 18+ · all sexes
Timeline Started 2021-05 · est. completion 2023-08
Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT04862923 ↗

Description as written by the study sponsor.

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor. Participants will be asked to complete some questionnaires about their diabetes treatment. Participants will complete these during their normally scheduled visits with the study doctor.

Treatments tested

Main thing measuredChange in glycated haemoglobin (HbA1c)
SponsorNovo Nordisk A/S
Conditions studiedDiabetes Mellitus, Type 2
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04862923 ↗